Yahoo
NasdaqCM - Nasdaq Real Time Price USD

SAB Biotherapeutics, Inc. (SABS)

3.2000 +0.1300 (+4.23%)
At close: October 28 at 4:00:00 PM EDT
3.1480 -0.0520 (-1.63%)
After hours: October 28 at 4:46:52 PM EDT
Trade SABS on Coinbase
Chart Range Bar
Loading chart for SABS
  • Previous Close 3.0700
  • Open 3.0400
  • Bid 3.1000 x 500
  • Ask 3.9400 x 200
  • Day's Range 3.0100 - 3.2200
  • 52 Week Range 2.4400 - 5.1500
  • Volume 347,699
  • Avg. Volume 532,940
  • Market Cap (intraday) 291.156M
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) --
  • EPS (TTM) -1.2900
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 11.64
  • Zacks Rating Neutral

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

www.sab.bio

86

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SABS
14.44%
S&P 500 (^GSPC)
13.13%

1-Year Return

SABS
5.96%
S&P 500 (^GSPC)
12.38%

3-Year Return

SABS
67.35%
S&P 500 (^GSPC)
88.08%

5-Year Return

SABS
96.08%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -22.49M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-20M
0
20M
40M
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00
11.64 Average
3.2000 Current
16.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/24/2026
Analyst Barclays
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 13

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    291.16M

  • Enterprise Value

    193.66M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.08

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    394.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.46%

  • Return on Equity (ttm)

    -11.27%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.79M

  • Diluted EPS (ttm)

    -1.2900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    102.63M

  • Total Debt/Equity (mrq)

    2.39%

  • Levered Free Cash Flow (ttm)

    -28.84M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.2000 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: